Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23496951 | 0.84 | TLR8 (0.42) | MAPTMEN1KMT2AAPEX1BCL2 | |
| SCHEMBL458586 | 0.76 | PABPC1 (0.55) | MAPTMEN1KMT2AAPEX1SMN1; SMN2 | |
| SCHEMBL29827450 | 0.76 | PABPC1 (0.55) | MAPTMEN1KMT2AAPEX1SMN1; SMN2 | |
| SCHEMBL6051235 | 0.74 | BCL2 (0.72) | MAPTMEN1KMT2AAPEX1BCL2 | |
| SCHEMBL13372234 | 0.72 | MAPT (0.59) | MAPTMEN1KMT2AAPEX1BCL2 | |
| SCHEMBL25719239 | 0.70 | MAPT (0.56) | MAPTMEN1KMT2AAPEX1BCL2 | |
| SCHEMBL22798938 | 0.69 | NPC1 (0.38) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL732391 | 0.68 | ALDH1A1 (0.44) | MAPTMEN1KMT2AAPEX1SMN1; SMN2 | |
| SCHEMBL13854898 | 0.68 | ALDH1A1 (0.57) | MAPTMEN1KMT2AAPEX1SMN1; SMN2 | |
| SCHEMBL28357765 | 0.66 | TYMS (0.52) | MAPTMEN1KMT2AAPEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | claimed |
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | UNIV COLORADO REGENTS (US) | 2023-04-27 | — | — | US | disclosed |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-06-17 | — | — | US | disclosed |
| CN-111542515-A | TOLL-like receptor 8(TLR8) specific antagonist and preparation method and application thereof | 科罗拉多州立大学董事会法人团体 | 2020-08-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | MAPT 4277/4885MEN1 4510/4885KMT2A 1642/4885 |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | MAPT 4286/4885MEN1 4538/4885KMT2A 1731/4885 |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | TLR8, TLR3, TLR9 | MAPT 4286/4885MEN1 4538/4885KMT2A 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.